Technical Analysis:
CRVL's stock shows a bearish trend in the short term, with RSI at 46.21 indicating neutral momentum. The stock is trading between its key moving averages, with SMA200 at $103.12 and SMA20 at $117.87. The recent price decline from $118.58 to $114.27 (-4.35%) suggests increasing selling pressure.
Price Levels:
- Support levels: $114.84 (Fibonacci S1), $111.54 (Fibonacci S2)
- Resistance levels: $125.53 (Fibonacci R1), $128.83 (Fibonacci R2)
News Impact:
- Recent insider selling activity: Director Alan Hoops sold 4,000 shares on Feb 7, 2025, indicating potential bearish sentiment from insiders
- Q3 2025 earnings showed positive results:
- Revenue up 9% to $179 million
- EPS increased 25% to $0.96
- Strong performance in patient management services
Prediction for Next Week:
Based on technical indicators and recent news:
- Bearish scenario (60% probability): Price likely to test Fibonacci S1 at $114.84
- Target price range: $114-116
- Key factors:
- Negative insider sentiment
- Below key moving averages
- Recent sharp decline (-4.35%)
- RSI showing neutral-to-bearish momentum
Trading Recommendation: SELL
- Entry point: Current price ($114.27)
- Stop loss: $116.50 (above recent high)
- Target: $114.00 (near Fibonacci S1)
- Risk/Reward ratio: 1:1.2
The stock shows bearish momentum in the short term despite strong fundamentals. The recent insider selling and technical indicators suggest further downside potential in the coming week.
Technical Analysis:
CRVL's stock shows a bearish trend in the short term, with RSI at 46.21 indicating neutral momentum. The stock is trading between its key moving averages, with SMA200 at $103.12 and SMA20 at $117.87. The recent price decline from $118.58 to $114.27 (-4.35%) suggests increasing selling pressure.
Price Levels:
- Support levels: $114.84 (Fibonacci S1), $111.54 (Fibonacci S2)
- Resistance levels: $125.53 (Fibonacci R1), $128.83 (Fibonacci R2)
News Impact:
- Recent insider selling activity: Director Alan Hoops sold 4,000 shares on Feb 7, 2025, indicating potential bearish sentiment from insiders
- Q3 2025 earnings showed positive results:
- Revenue up 9% to $179 million
- EPS increased 25% to $0.96
- Strong performance in patient management services
Prediction for Next Week:
Based on technical indicators and recent news:
- Bearish scenario (60% probability): Price likely to test Fibonacci S1 at $114.84
- Target price range: $114-116
- Key factors:
- Negative insider sentiment
- Below key moving averages
- Recent sharp decline (-4.35%)
- RSI showing neutral-to-bearish momentum
Trading Recommendation: SELL
- Entry point: Current price ($114.27)
- Stop loss: $116.50 (above recent high)
- Target: $114.00 (near Fibonacci S1)
- Risk/Reward ratio: 1:1.2
The stock shows bearish momentum in the short term despite strong fundamentals. The recent insider selling and technical indicators suggest further downside potential in the coming week.